日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

激酶受损的 BTK 突变易受临床阶段 BTK 和 IKZF1/3 降解剂 NX-2127 的影响

Skye Montoya #, Jessie Bourcier #, Mark Noviski #, Hao Lu #, Meghan C Thompson, Alexandra Chirino, Jacob Jahn, Anya K Sondhi, Stefan Gajewski, Ying Siow May Tan, Stephanie Yung, Aleksandra Urban, Eric Wang, Cuijuan Han, Xiaoli Mi, Won Jun Kim, Quinlan Sievers, Paul Auger, Hugo Bousquet, Nivetha Brat

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

NRX-0492 可降解野生型和 C481 突变型 BTK,并在 CLL 患者来源的异种移植模型中显示出体内活性。

Deyi Zhang ,Hailey M Harris ,Jonathan Chen ,Jen Judy ,Gabriella James ,Aileen Kelly ,Joel McIntosh ,Austin Tenn-McClellan ,Eileen Ambing ,Ying Siow Tan ,Hao Lu ,Stefan Gajewski ,Matthew C Clifton ,Stephanie Yung ,Daniel W Robbins ,Mehdi Pirooznia ,Sigrid S Skånland ,Erika Gaglione ,Maissa Mhibik ,Chingiz Underbayev ,Inhye E Ahn ,Clare Sun ,Sarah E M Herman ,Mark Noviski ,Adrian Wiestner

NR4A nuclear receptors restrain B cell responses to antigen when second signals are absent or limiting

当第二信号缺失或限制时,NR4A 核受体会抑制 B 细胞对抗原的反应

Corey Tan #, Ryosuke Hiwa #, James L Mueller, Vivasvan Vykunta, Kenta Hibiya, Mark Noviski, John Huizar, Jeremy F Brooks, Jose Garcia, Cheryl Heyn, Zhongmei Li, Alexander Marson, Julie Zikherman

IgM and IgD B cell receptors differentially respond to endogenous antigens and control B cell fate

IgM 和 IgD B 细胞受体对内源性抗原的反应不同,并控制 B 细胞的命运。

Mark Noviski ,James L Mueller ,Anne Satterthwaite ,Lee Ann Garrett-Sinha ,Frank Brombacher ,Julie Zikherman

An extracatalytic function of CD45 in B cells is mediated by CD22

CD45 在 B 细胞中的催化功能由 CD22 介导

Sarah Coughlin, Mark Noviski, James L Mueller, Ammarina Chuwonpad, William C Raschke, Arthur Weiss, Julie Zikherman